{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"65"}],"units":"Participants"}],"description":"Proportion of patients who experience any grade 3 or higher CTC AE Version 4 adverse experience","groups":[{"description":"Patients in phase I received vorinostat at 180 mg/m\\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\\^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\n3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo intensity-modulated radiation therapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Arm 1, Phase I Vorinostat 180 mg/m^2"},{"description":"Patients received a higher dose of vorinostat at 230 mg/m\\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\\^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\n3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo intensity-modulated radiation therapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG001","title":"Arm 2, Phase I Vorinostat 230 mg/m^2"},{"description":"Patients received a higher dose of vorinostat at 230 mg/m\\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m\\^2/ day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\n3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo intensity-modulated radiation therapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG002","title":"Arm 3, Phase II Evaluation Vorinostat 230 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients enrolled on Arm 1 and 2 received at least one dose of chemoradiation therapy. Two patients enrolled on arm 3 did not receive protocol therapy prior to date of removal from protocol therapy.","reportingStatus":"POSTED","timeFrame":"Planned 7 weeks during chemoradiotherapy","title":"Incidence of Toxicity During Chemoradiation Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}